Mallinckrodt Pharmaceuticals elects David Norton to board
Mr. Norton, who has more than 30 years of experience in the biopharmaceutical industry, will serve as an independent director on the board's Human Resources and Compensation Committee and Portfolio Committee.
Mr. Norton retired in 2011 as Company Group Chairman, Global Pharmaceuticals, for Johnson & Johnson.
His 32-year tenure at Johnson & Johnson spanned marketing and country management roles across Belgium, Australia and New Zealand; and serving as president of the Janssen Pharmaceutica business in the U.S., group chairman of the Pharmaceuticals Group for Europe, Middle East and Africa, and then for the U.S. and Canada business, as well as company group chairman, worldwide commercial and operations, for Johnson & Johnson's CNS and virology business.
Mr. Norton is currently chairman of the board of directors of VIVUS, Inc.
He previously served as a director for INC Research Holdings Inc. and Savient Pharmaceuticals Inc. ■
LATEST MOVES FROM United Kingdom
- Silence Therapeutics appoints Annalisa Jenkins to board
- Augean appoints two directors
- Syncona appoints Robert Hutchinson as director
- Virgin Money Holdings to appoint Amy Stirling to board
- Bovis Homes appoints Mike Stansfield as director
More inside POST